BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 31896573)

  • 1. Mass spectrometry-based selectivity profiling identifies a highly selective inhibitor of the kinase MELK that delays mitotic entry in cancer cells.
    McDonald IM; Grant GD; East MP; Gilbert TSK; Wilkerson EM; Goldfarb D; Beri J; Herring LE; Vaziri C; Cook JG; Emanuele MJ; Graves LM
    J Biol Chem; 2020 Feb; 295(8):2359-2374. PubMed ID: 31896573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. OTSSP167 Abrogates Mitotic Checkpoint through Inhibiting Multiple Mitotic Kinases.
    Ji W; Arnst C; Tipton AR; Bekier ME; Taylor WR; Yen TJ; Liu ST
    PLoS One; 2016; 11(4):e0153518. PubMed ID: 27082996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of maternal embryonic leucine zipper kinase with OTSSP167 displays potent anti-leukemic effects in chronic lymphocytic leukemia.
    Zhang Y; Zhou X; Li Y; Xu Y; Lu K; Li P; Wang X
    Oncogene; 2018 Oct; 37(41):5520-5533. PubMed ID: 29895969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MELK expression in ovarian cancer correlates with poor outcome and its inhibition by OTSSP167 abrogates proliferation and viability of ovarian cancer cells.
    Kohler RS; Kettelhack H; Knipprath-Mészaros AM; Fedier A; Schoetzau A; Jacob F; Heinzelmann-Schwarz V
    Gynecol Oncol; 2017 Apr; 145(1):159-166. PubMed ID: 28214016
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Maternal embryonic leucine zipper kinase is a novel target for diffuse large B cell lymphoma and mantle cell lymphoma.
    Maes A; Maes K; Vlummens P; De Raeve H; Devin J; Szablewski V; De Veirman K; Menu E; Moreaux J; Vanderkerken K; De Bruyne E
    Blood Cancer J; 2019 Nov; 9(12):87. PubMed ID: 31740676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel carbon-11 radiolabeled maternal embryonic leucine zipper kinase inhibitor for PET imaging of triple-negative breast cancer.
    Tang R; Gai Y; Li K; Hu F; Gong C; Wang S; Feng F; Altine B; Hu J; Lan X
    Bioorg Chem; 2021 Feb; 107():104609. PubMed ID: 33454507
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enigmatic MELK: The controversy surrounding its complex role in cancer.
    McDonald IM; Graves LM
    J Biol Chem; 2020 Jun; 295(24):8195-8203. PubMed ID: 32350113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Maternal embryonic leucine zipper kinase serves as a poor prognosis marker and therapeutic target in osteosarcoma.
    Jeddo SFA; Wei X; Li K; Li X; Yang Q; Dongol S; Li J
    Oncol Rep; 2020 Sep; 44(3):1037-1048. PubMed ID: 32705239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MELK Inhibition in Diffuse Intrinsic Pontine Glioma.
    Meel MH; de Gooijer MC; Guillén Navarro M; Waranecki P; Breur M; Buil LCM; Wedekind LE; Twisk JWR; Koster J; Hashizume R; Raabe EH; Montero Carcaboso A; Bugiani M; van Tellingen O; van Vuurden DG; Kaspers GJL; Hulleman E
    Clin Cancer Res; 2018 Nov; 24(22):5645-5657. PubMed ID: 30061363
    [No Abstract]   [Full Text] [Related]  

  • 10. [
    Hu F; Gong C; Gai Y; Jiang D; Liu Q; Wang S; Hu M; Pi R; Shu H; Hu J; Lan X
    Mol Pharm; 2021 Sep; 18(9):3544-3552. PubMed ID: 34482695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Up-regulation of MELK by E2F1 promotes the proliferation in cervical cancer cells.
    Sun H; Ma H; Zhang H; Ji M
    Int J Biol Sci; 2021; 17(14):3875-3888. PubMed ID: 34671205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genome-wide effects of MELK-inhibitor in triple-negative breast cancer cells indicate context-dependent response with p53 as a key determinant.
    Simon M; Mesmar F; Helguero L; Williams C
    PLoS One; 2017; 12(2):e0172832. PubMed ID: 28235006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MELK-T1, a small-molecule inhibitor of protein kinase MELK, decreases DNA-damage tolerance in proliferating cancer cells.
    Beke L; Kig C; Linders JT; Boens S; Boeckx A; van Heerde E; Parade M; De Bondt A; Van den Wyngaert I; Bashir T; Ogata S; Meerpoel L; Van Eynde A; Johnson CN; Beullens M; Brehmer D; Bollen M
    Biosci Rep; 2015 Oct; 35(6):. PubMed ID: 26431963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mitotic MELK-eIF4B signaling controls protein synthesis and tumor cell survival.
    Wang Y; Begley M; Li Q; Huang HT; Lako A; Eck MJ; Gray NS; Mitchison TJ; Cantley LC; Zhao JJ
    Proc Natl Acad Sci U S A; 2016 Aug; 113(35):9810-5. PubMed ID: 27528663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multi-kinase inhibitor C1 triggers mitotic catastrophe of glioma stem cells mainly through MELK kinase inhibition.
    Minata M; Gu C; Joshi K; Nakano-Okuno M; Hong C; Nguyen CH; Kornblum HI; Molla A; Nakano I
    PLoS One; 2014; 9(4):e92546. PubMed ID: 24739874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of a potent inhibitor of MELK that inhibits expression of the anti-apoptotic protein Mcl-1 and TNBC cell growth.
    Edupuganti R; Taliaferro JM; Wang Q; Xie X; Cho EJ; Vidhu F; Ren P; Anslyn EV; Bartholomeusz C; Dalby KN
    Bioorg Med Chem; 2017 May; 25(9):2609-2616. PubMed ID: 28351607
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mitotic Checkpoint Kinase Mps1 Has a Role in Normal Physiology which Impacts Clinical Utility.
    Martinez R; Blasina A; Hallin JF; Hu W; Rymer I; Fan J; Hoffman RL; Murphy S; Marx M; Yanochko G; Trajkovic D; Dinh D; Timofeevski S; Zhu Z; Sun P; Lappin PB; Murray BW
    PLoS One; 2015; 10(9):e0138616. PubMed ID: 26398286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kinome Profiling of Primary Endometrial Tumors Using Multiplexed Inhibitor Beads and Mass Spectrometry Identifies SRPK1 as Candidate Therapeutic Target.
    Kurimchak AM; Kumar V; Herrera-Montávez C; Johnson KJ; Srivastava N; Davarajan K; Peri S; Cai KQ; Mantia-Smaldone GM; Duncan JS
    Mol Cell Proteomics; 2020 Dec; 19(12):2068-2090. PubMed ID: 32994315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elucidating the Role of the Maternal Embryonic Leucine Zipper Kinase in Adrenocortical Carcinoma.
    Kiseljak-Vassiliades K; Zhang Y; Kar A; Razzaghi R; Xu M; Gowan K; Raeburn CD; Albuja-Cruz M; Jones KL; Somerset H; Fishbein L; Leong S; Wierman ME
    Endocrinology; 2018 Jul; 159(7):2532-2544. PubMed ID: 29790920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mitotic arrest and slippage induced by pharmacological inhibition of Polo-like kinase 1.
    Raab M; Krämer A; Hehlgans S; Sanhaji M; Kurunci-Csacsko E; Dötsch C; Bug G; Ottmann O; Becker S; Pachl F; Kuster B; Strebhardt K
    Mol Oncol; 2015 Jan; 9(1):140-54. PubMed ID: 25169932
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.